rpoB mutations and their association with rifampicin resistance in clinical Staphylococcus epidermidis
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Sofie Marie Edslev und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sequencing and Bioinformatics, Statens Serum Institut, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Rifampin, Staphylococcus epidermidis, Drug Resistance, Bacterial, DNA-Directed RNA Polymerases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nyckelfonden at Örebro University Hospital.
Abstract (Originalsprache)
Background
Staphylococcus epidermidis is a ubiquitous member of the healthy skin and mucous microbiota but is also an opportunistic pathogen responsible for various infections, often treated with antibiotics like rifampicin. Resistance to rifampicin in S. epidermidis arises primarily through nonsynonymous mutations in the rpoB gene.
Objectives
To investigate the prevalence of rpoB mutations and their association with phenotypic rifampicin resistance in clinical S. epidermidis isolates from Denmark, France, and Sweden.
Methods
All clinical isolates (N = 942) were whole-genome sequenced to identify mutations in rpoB and subsequently linked to phenotypic rifampicin resistance based on antimicrobial susceptibility testing.
Results
A total of 64 (6.8%) isolates were resistant to rifampicin. They carried all mutational changes in the rifampicin resistance-determining region (RRDR). Among 12 identified nonsynonymous mutations, 11 were exclusively observed in resistant strains, including novel mutations not previously described in S. epidermidis.
Conclusions
This study highlights the diverse genetic variants of rpoB associated with rifampicin resistance in clinical S. epidermidis isolates, including novel mutations. The strong correlation between mutational changes in RRDR and phenotypic resistance reinforces the role of rpoB mutations as a primary mechanism of resistance in clinical isolates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Sequencing and Bioinformatics, Statens Serum Institut, Copenhagen, Denmark.
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS), Basel, Switzerland.
- Department of Clinical Microbiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Department of Immunology & Microbiology, University of Copenhagen, Copenhagen, Denmark.
- Service de Bactériologie, Centre National de Référence des Staphylocoques, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.
- Equipe StaPath, CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, Lyon, France.
ORCID-Profile: Mia Aarris, Camille Kolenda, Frederic Laurent, Bo Söderquist
Förderung
- Nyckelfonden at Örebro University Hospital
Zitieren
APA
Edslev, S. M., Aarris, M., Nielsen, K. L., Hertz, F. B., Johannesen, T. B., Kolenda, C., Laurent, F., Månsson, E., Söderquist, B., & Stegger, M. (2025). rpoB mutations and their association with rifampicin resistance in clinical Staphylococcus epidermidis. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf035
Vancouver
Edslev SM, Aarris M, Nielsen KL, Hertz FB, Johannesen TB, Kolenda C, et al. rpoB mutations and their association with rifampicin resistance in clinical Staphylococcus epidermidis. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf035
BibTeX
@article{Edslev2025,
author = {Edslev, Sofie Marie and Aarris, Mia and Nielsen, Karen Leth and Hertz, Frederik B and Johannesen, Thor Bech and Kolenda, Camille and Laurent, Frederic and Månsson, Emeli and Söderquist, Bo and Stegger, Marc},
title = {rpoB mutations and their association with rifampicin resistance in clinical Staphylococcus epidermidis},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf035}
}
EUVIMED